Article
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.
Oncogene - 23 Mar 2017
Castagnoli L, Ghedini G C, Koschorke A, Triulzi T, Dugo M, Gasparini P, Casalini P, Palladini A, Iezzi M, Lamolinara A, Lollini P L, Nanni P, Chiodoni C, Tagliabue E, Pupa S M
Abstract excerpt
We have previously shown that the d16HER2 splice variant is linked to HER2-positive breast cancer (BC) tumorigenesis, progression and response to Trastuzumab. However, the mechanisms by which d16HER2 contributes to HER2-driven aggressiveness and targeted therapy susceptibility remain uncertain. Here, we report that the d16HER2-positive mammary tumor cell lines MI6 and MI7, derived from spontaneous lesions of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.